Friday, November 20, 2026

Arcturus Therapeutics Stock Was 23.09% Up On Thursday

ViaNews Editorial Team

November 16, 2023

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Arcturus Therapeutics Stock Was 23.09% Up On Thursday

(VIANEWS) - The NASDAQ ended the session with Arcturus Therapeutics (ARCT) rising 23.09% to $23.88 on Thursday while NASDAQ jumped 0.07% to $14,103.84.

Arcturus Therapeutics's last close was $19.40, 48.61% below its 52-week high of $37.75.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

Earnings Per Share

As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $3.03.

PE Ratio

Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 7.88. Meaning, the purchaser of the share is investing $7.88 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 35.22%.

Yearly Top and Bottom Value

Arcturus Therapeutics's stock is valued at $23.88 at 02:04 EST, way under its 52-week high of $37.75 and way higher than its 52-week low of $14.21.

More news about Arcturus Therapeutics (ARCT).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 16 Nov 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.